Development, Immunogenicity and Protective Efficacy of an Associated Inactivated Vaccine Against Highly Pathogenic Avian Influenza and Newcastle Disease in Chickens
Authors:
- Yeldos MyrzakhmetovYMYeldos Myrzakhmetov
- Nurika AssanzhanovaNANurika Assanzhanova
- Sholpan RyskeldinovaSRSholpan Ryskeldinova
- Aigerim MailybayevaAMAigerim Mailybayeva
- Aigerim SagymbayevaASAigerim Sagymbayeva
- Yerken KozhamkulovYKYerken Kozhamkulov
- Ekaterina YamanovaEYEkaterina Yamanova
- Rassul SidikhovRSRassul Sidikhov
- Nurlan S. KozhabergenovNKNurlan S. Kozhabergenov
- Bekbolat UsserbayevBUBekbolat Usserbayev
- Kuanysh ZhekebekovKZKuanysh Zhekebekov
- Sergazy NurabayevSNSergazy Nurabayev
Open Access
Abstract
Background: The simultaneous circulation of highly pathogenic avian influenza (HPAI) H5N8 (clade 2.3.4.4b) and virulent Newcastle disease virus (NDV) genotype VII creates a cumulative risk for the poultry industry, rendering monovalent vaccination insufficient. This study aimed to develop and evaluate a combined inactivated vaccine against AIV H5N8 and NDV genotype VII based on local endemic strains. Methods: The vaccine was formulated as a water-in-oil emulsion (30:70) using Montanide™ ISA 78 VG. Evaluation included physicochemical characterization, safety assessment in chickens, immunogenicity evaluation via the hemagglutination inhibition (HI) test, and protective efficacy following challenge with virulent isolates. Results: The formulation demonstrated high stability and complete safety without adverse reactions. By 28 days post-immunization, the vaccine induced a robust, balanced humoral response with antibody titers reaching 9.10 ± 0.23 log2 against NDV and 9.00 ± 0.26 log2 against AIV, indicating no antigenic interference. Upon challenge, the vaccinated group exhibited 100% clinical protection and survival, compared to 100% mortality in controls. Furthermore, vaccination significantly reduced viral shedding, limiting horizontal spread. Conclusions: The developed combined inactivated vaccine demonstrates high safety, stability, and protective efficacy. It represents a promising candidate for comprehensive specific prophylaxis in endemic regions, effectively limiting horizontal pathogen transmission and mitigating economic losses in poultry production.Keywords
Funding Information
- Targeted Funding Program “Biological Safety of the Republic of Kazakhstan: Threat Assessment, Scientific and Technical Foundations for Their Prevention and Elimination” (O.001B)
This publication has 32 references indexed in Scilit:
- Comparative Study of Vaccine‐Induced Humoral Immune Response Against Newcastle Disease Virus and Avian Influenza Virus (H9N2) in Different Bird Species of Mashhad Birds GardenVeterinary Medicine and Science, 2025
- Evaluation of the Newcastle disease virus genotype VII–mismatched vaccines in SPF chickens: A challenge efficacy studyVeterinary and Animal Science, 2024
- Evaluation of inactivated avian influenza virus and Newcastle disease virus bivalent vaccination program against newly circulated H5N8 and NDV strainsPoultry Science, 2023
- A single dose of inactivated oil-emulsion bivalent H5N8/H5N1 vaccine protects chickens against the lethal challenge of both highly pathogenic avian influenza virusesComparative Immunology, Microbiology and Infectious Diseases, 2021
- Co-inections of domestic and wild birds with avian influenza and Newcastle disease viruses: implications for control and genetic mutationsVeterinary Research Communications, 2020
- Immune responses of poultry to Newcastle disease virusDevelopmental & Comparative Immunology, 2013
- Evolutionary dynamics of Newcastle disease virusVirology, 2009
- New horizons in adjuvants for vaccine developmentTrends in Immunology, 2009
- Adjuvants designed for veterinary and human vaccinesVaccine, 2001
- Adjuvants—a classification and review of their modes of actionVaccine, 1997